Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2021 - 09 - 01 save search
ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting
Published: 2021-09-01 (Crawled : 13:00) - nantkwest.com
IBRX | $4.815 -12.3% -14.02% 7.9M
|
Manufacturing
|
| O: 0.97%
H: 3.13%
C: 2.7%
presentation phase 2 phase 2/3 results cancer trial trial results bladder
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting
Published: 2021-09-01 (Crawled : 13:00) - globenewswire.com
ENTX | $2.07 -6.76% -7.25% 160K
|
Health Technology
|
| O: 0.82%
H: 5.26%
C: 4.88%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.01%
H: 0.25%
C: -0.98%
presentation phase 2 osteoporosis eb613
Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases
Published: 2021-09-01 (Crawled : 12:15) - biospace.com/
BBI | $2.12 16.04%
|
Health Technology
|
| O: 0.2%
H: 1.35%
C: 1.22%
disease phase 1 biotech iot phase 2 phase 3
White Metal JV Partner Leocor Gold Plans Phase 1 Work Program on the Startrek Gold Property, Central Newfoundland
Published: 2021-09-01 (Crawled : 12:15) - globenewswire.com
NFGC | News | $3.66 -3.68% 0.0% 470K
|
| Email alert
Add to watchlist
phase 2 phase 3 phase 1 leo
Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
Published: 2021-09-01 (Crawled : 12:15) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.64%
H: 0.0%
C: -2.2%
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: -2.6%
H: 6.97%
C: 6.81%
phase 2 europe ongoing results trial preclinical pre-clinical
Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases
Published: 2021-09-01 (Crawled : 12:15) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.1%
H: 0.09%
C: -0.44%
RIGL | $1.125 -1.32% -1.33% 6.4M
|
Health Technology
|
| O: -0.26%
H: 8.84%
C: 8.44%
covid disease phase 2 infectious disease trial
Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)
Published: 2021-09-01 (Crawled : 12:00) - biospace.com/
XERS | $1.765 -0.84% -0.85% 710K
|
Health Technology
|
| O: 1.81%
H: 1.07%
C: -0.36%
phase 1 phase 2 phase 3 enroll
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.